Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 9—September 2011
Research

Estimating Effect of Antiviral Drug Use during Pandemic (H1N1) 2009 Outbreak, United States

Charisma Y. Atkins, Anita Patel, Thomas H. Taylor, Matthew Biggerstaff, Toby L. Merlin, Stephanie M. Dulin, Benjamin A. Erickson, Rebekah H. Borse, Robert Hunkler, and Martin I. Meltzer
Author affiliations: Author affiliations: Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (C.Y. Atkins, A. Patel, T.H. Taylor, Jr., M. Biggerstaff, T.L. Merlin, S.M. Dulin, B.A. Erikson, R.H. Borse, M.I. Meltzer); IMS Health, Fountain Hills, Arizona, USA (R. Hunkler)

Main Article

Table 5

Estimates of hospitalizations averted, by age group, assuming lower and upper estimates of influenza antiviral drug effectiveness, United States, 2009–2010*

Drug effectiveness estimate No. hospitalizations averted, by patient age group, y, median (range)
0–17 18–64 >65 Total
Lower 1,848 (1,527–2,081) 5,158 (4,264–5,803) 1,421 (1,171–1,595) 8,427 (6,961–9,479)
Upper 2,687 (2,221–3,027) 7,586(6,270–8,534) 2,368 (1,951–2,659) 12,641 (10,442–14,219)

*Estimates of antiviral drug effectiveness are shown Table 2 (source, Table 1). Lower, median, and upper estimates are generated by using the range of age-specific probabilities of hospitalization, given influenza-related clinical illness (Table 2).

Main Article

Page created: June 19, 2012
Page updated: June 19, 2012
Page reviewed: June 19, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external